Yong Jian, Gengshen Mo, Weiyuan Xu, Yao Liu, Zhichao Zhang, Yinghui Ding, Ruonan Gao, Jiao Xu, Jiang Zhu, Kun Shu, Zhihan Yan, Fabio Carniato, Carlos Platas-Iglesias, Fangfu Ye, Mauro Botta, Lixiong Dai
In recent years, pyclen-based complexes have attracted a great deal of interest as magnetic resonance imaging (MRI) contrast agents (CAs) and luminescent materials, as well as radiopharmaceuticals. Remarkably, gadopiclenol, a Gd(III) bishydrated complex featuring a pyclen-based heptadentate ligand, received approval as a novel contrast agent for clinical MRI application in 2022. To maximize stability and efficiency, two novel chiral pyclen-based chelators and their complexes were developed in this study. Gd-X-PCTA-2 showed significant enhancements in both thermodynamic and kinetic stabilities compared to those of the achiral parent derivative Gd-PCTA ...
April 20, 2024: Inorganic Chemistry